Advertisement

Rheumatology International

, Volume 34, Issue 2, pp 199–205 | Cite as

A meta-analysis of the association of IL-6 −174 G/C and −572 G/C polymorphisms with systemic lupus erythematosus risk

  • Zaixing YangEmail author
  • Yan Liang
  • Baodong Qin
  • Renqian ZhongEmail author
Original Article

Abstract

The results from previous studies on association of IL-6 −174 G/C and −572 G/C polymorphisms with the risk of systemic lupus erythematosus (SLE) remained inconsistent. Therefore, a meta-analysis was performed to assess the association between these two polymorphisms and SLE susceptibility. A literature-based search was conducted to identify all relevant studies. Pooled data were estimated by fixed- and random-effects models when appropriate. Nine publications were included in the meta-analysis, seven for −174 G/C polymorphism and three for −572 G/C polymorphism. The results indicated that IL-6 −174 G/C polymorphism was significantly associated with SLE risk for recessive model and allele analysis in overall populations (OR 1.64, 95 % CI 1.10–2.45, P = 0.016; and 1.34, 1.05–1.72, P = 0.019, respectively, for recessive model and allele analysis) or in Caucasians (OR 1.37, 95 % CI 1.04–1.82, P = 0.027; and 1.27, 1.04–1.54, P = 0.018, respectively, for recessive model and allele analysis). Also, significant association between IL-6 −572 G/C polymorphism and SLE was found under recessive model (OR 1.49, 95 % CI 1.10–2.01, P = 0.009), but not under dominant model and allele analysis (OR 1.05, 95 % CI 0.77–1.43, P = 0.750; and 1.21, 1.00–1.48, P = 0.054, respectively, for dominant model and allele analysis). Additionally, our meta-analysis showed that IL-6 −174 G/C polymorphism was significantly associated with discoid skin lesions (P < 0.05). The present study indicates that IL-6 −174 G/C and −572 G/C polymorphisms could be candidates for susceptibility to SLE. Furthermore, a large number of studies should be performed to explore the association of IL-6 polymorphisms with the risk and clinical characteristics of SLE patients in different ethnics.

Keywords

Interleukin 6 Systemic lupus erythematosus Polymorphism Meta-analysis 

Notes

Acknowledgments

This study was supported by Grants from the China National Natural Science Foundation Council (81001333 and 81102262) and Changzheng Hospital Funds for Young Scholar (2011CZQN06).

Conflict of interest

None.

References

  1. 1.
    Yasutomo K (2003) Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus. Rheumatology (Oxford) 42:214–222CrossRefGoogle Scholar
  2. 2.
    Wakeland EK, Liu K, Graham RR, Behrens TW (2001) Delineating the genetic basis of systemic lupus erythematosus. Immunity 15:397–408PubMedCrossRefGoogle Scholar
  3. 3.
    Ruiz-Narvaez EA, Fraser PA, Palmer JR, Cupples LA, Reich D, Wang YA, Rioux JD, Rosenberg L. MHC region and risk of systemic lupus erythematosus in African American women. Hum Genet. 2011 Jun 22. Epub ahead of printGoogle Scholar
  4. 4.
    Lessard CJ, Adrianto I, Kelly JA, Kaufman KM, Grundahl KM, Adler A, Williams AH, Gallant CJ, Marta E et al (2011) Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet 88(1):83–91PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, Xu JH, Cai ZM et al (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41(11):1234–1237PubMedCrossRefGoogle Scholar
  6. 6.
    Kiberd BA (1993) Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 4:58–61PubMedGoogle Scholar
  7. 7.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A (2010) Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Fas lpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 37:60–70PubMedCrossRefGoogle Scholar
  8. 8.
    Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM et al (2007) Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27:461–466PubMedCrossRefGoogle Scholar
  9. 9.
    Mellor-Pita S, Citores MJ, Castejon R, Yebra-Bango M, Tutor-Ureta P, Rosado S et al (2009) Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. Cytometry B Clin Cytom 76B:261–270CrossRefGoogle Scholar
  10. 10.
    Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62:542–552PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:589–624CrossRefGoogle Scholar
  12. 12.
    Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889–894PubMedCrossRefGoogle Scholar
  13. 13.
    Egger M, Davey SG, Schneider M, Minder C (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRefGoogle Scholar
  14. 14.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRefGoogle Scholar
  15. 15.
    Linker-Israeli M, Wallace DJ, Prehn J, Michael D, Honda M, Taylor KD, Paul-Labrador M, Fischel-Ghodsian N, Fraser PA, Klinenberg JR (1999) Association of IL-6 gene alleles with systemic lupus erythematosus (SLE) and with elevated IL-6 expression. Genes Immun 1:45–52PubMedCrossRefGoogle Scholar
  16. 16.
    Chua KH, Kee BP, Tan SY, Lian LH (2009) Interleukin-6 promoter polymorphisms (−174 G/C) in Malaysian patients with systemic lupus erythematosus. Braz J Med Biol Res 42(6):551–555PubMedCrossRefGoogle Scholar
  17. 17.
    Godarzi EM, Sarvestani EK, Aflaki E, Amirghofran Z (2011) Interleukin-6 gene polymorphism in Iranian patients with systemic lupus erythematosus. Clin Rheumatol 30:179–184PubMedCrossRefGoogle Scholar
  18. 18.
    Santos MJ, Fernandes D, Capela S, da Silva JC, Fonseca JE (2011) Interleukin-6 promoter polymorphism −174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. Clin Rheumatol 30:409–413PubMedCrossRefGoogle Scholar
  19. 19.
    Hrycek A, Siekiera U, Cieślik P, Szkróbka W (2005) HLA-DRB1 and -DQB1 alleles and gene polymorphisms of selected cytokines in systemic lupus erythematosus. Rheumatol Int 26:1–6PubMedCrossRefGoogle Scholar
  20. 20.
    Schotte H, Schlüter B, Rust S, Assmann G, Domschke W, Gaubitz M (2001) Interleukin-6 promoter polymorphism (–174 G/C) in Caucasian German patients with systemic lupus erythematosus. Rheumatology (Oxford) 40:393–400CrossRefGoogle Scholar
  21. 21.
    Guarnizo-Zuccardi P, Lopez Y, Giraldo M, Garcia N, Rodriguez L, Ramirez L, Uribe O, Garcia L, Vasquez G (2007) Cytokine gene polymorphisms in Colombian patients with systemic lupus erythematosus. Tissue Antigens 70:376–382PubMedCrossRefGoogle Scholar
  22. 22.
    Huang CM, Huo AP, Tsai CH, Chen CL, Tsai FJ (2006) Lack of association of interleukin-6 and interleukin-8 gene polymorphisms in Chinese patients with systemic lupus erythematosus. J Clin Lab Anal 20:255–259PubMedCrossRefGoogle Scholar
  23. 23.
    Jeon JY, Kim HA, Kim SH, Park HS, Suh CH (2010) Interleukin 6 gene polymorphisms are associated with systemic lupus erythematosus in Koreans. J Rheumatol 37:2251–2258PubMedCrossRefGoogle Scholar
  24. 24.
    Ripley BJ, Goncalves B, Isenberg DA, Latchman DS, Rahman A (2005) Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 64:849–853PubMedCrossRefGoogle Scholar
  25. 25.
    Lee YH, Lee HS, Choi SJ, Ji JD, Song GG (2012) The association between interleukin-6 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus 21:60–67PubMedCrossRefGoogle Scholar
  26. 26.
    Nurnberg W, Haas N, Schadendorf D, Czarnetzki BM (1995) Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp Dermatol 4:52–57PubMedCrossRefGoogle Scholar
  27. 27.
    Muller-Steinhardt M, Fricke L, Muller B, Ebel B, Kirchner H, Hartel C (2004) Cooperative influence of the interleukin-6 promoter polymorphisms -597, -572 and -174 on long-term kidney allograft survival. Am J Transpl 4:402–406CrossRefGoogle Scholar
  28. 28.
    Hamid YH, Rose CS, Urhammer SA, Glumer C, Nolsoe R, Kristiansen OP, Mandrup-Poulsen T, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O (2005) Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 48:251–260PubMedCrossRefGoogle Scholar
  29. 29.
    Cussigh A, Falleti E, Fabris C, Bitetto D, Cmet S, Fontanini E, Bignulin S, Fornasiere E, Fumolo E, Minisini R, Pirisi M, Toniutto P (2011) Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics 63:33–41PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Laboratory Diagnostics, Changzheng HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations